New findings reveal phenotypic clusters in pediatric Behçet’s disease, offering insights into its variable presentation and highlighting the need for improved diagnostic awareness in children.

When to use apremilast and biologics and how to deal with vascular involvement were some of the main areas to be updated in forthcoming EULAR recommendations for Behçet's disease.

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing therapies for rare diseases with unmet medical needs, issued a shareholder update outlining key clinical and strategic ...

Behçet disease is a chronic multisystem inflammatory disorder with oral and genital ulcers present in up to 95% of patients. Skin manifestations are often papulopustular rashes or erythema ...

Soligenix's Treatment Of Behçet's Disease Soligenix's drug candidate for treating Behçet’s disease is SGX945. Dusquetide, the active ingredient in SGX945, is an innate defense regulator (IDR ...

There are approximately 18,000 known cases of Behçet's Disease in the U.S. and over 50,000 in Europe. There are as many as 1,000,000 people worldwide living with Behçet's Disease.

Dusquetide, the active ingredient in SGX945 (Behçet's Disease) and SGX942 (oral mucositis), is an innate defense regulator (IDR), a new class of short, synthetic peptides. It has a novel ...

Immunoglobulin A nephropathy (also known as IgA nephropathy or Berger's disease) is an autoimmune disease that affects the kidneys. It develops when too much of the protein IgA builds up in the ...